Compare Danaher Corporation (DHR) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Mondaycom Ltd — how do they compare? Danaher Corporation trades at $207.02 (market cap $145.83B), while Mondaycom Ltd trades at $84.9 (market cap $3.70B). The key difference: Danaher Corporation is far larger — about 39.4× Mondaycom Ltd's market cap, and Danaher Corporation pays a 0.77% dividend while Mondaycom Ltd pays none. Which is the better fit depends on your goals.
| DHR | MNDY | |
|---|---|---|
Market Cap | $145.83B | $3.70B |
Sector | Health | Technology |
52-Week High | $242.05 | $219.15 |
52-Week Low | $161.91 | $58.81 |
Enterprise Value | $168.04B | $2.86B |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
MNDY trades at $84.52, down 4.63% amid mixed signals. The stock shows strong fundamentals with Q2 2026 EPS of $1.48 beating estimates by 33%, revenue growth of 22% year-over-year, and robust gross margins of 88.74%. However, technical indicators are neutral with support at $83 and resistance at $89. Recent news highlights AI product growth but weaker Q3 revenue guidance caused a sell-off.
Outlook remains cautiously optimistic with a $113.38 consensus price target implying 34% upside. Key risks include slowing revenue growth guidance and competitive pressures. The 76% buy rating from analysts supports long-term potential, but near-term volatility may persist due to execution concerns and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
